Proliferative Effects of Erythropoietin on Human Endometrium
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03060603|
Recruitment Status : Completed
First Posted : February 23, 2017
Last Update Posted : January 23, 2018
|Condition or disease||Intervention/treatment|
|Anemia Endometrial Diseases||Drug: Erythropoietin|
|Study Type :||Observational|
|Actual Enrollment :||14 participants|
|Official Title:||Proliferative Effects of Erythropoietin on Human Endometrium|
|Actual Study Start Date :||February 23, 2017|
|Actual Primary Completion Date :||December 29, 2017|
|Actual Study Completion Date :||January 15, 2018|
Recombinant Human Erythropoietin, EPREX 4000 IU/0.4 ml, three times in a week, until the correction of anemia, approximately two months.
Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.
Other Name: Recombinant Human Erythropoietin, EPREX 4000 IU/0.4 ml
- Change from Baseline Endometrial Thickness Confirmed by Transvaginal Ultrasonography at 3th and 30th Days [ Time Frame: within the first 3 and 30 days (plus or minus 3 days) after the erythropoietin treatment ]Change from Baseline Endometrial Thickness Confirmed by Transvaginal
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03060603
|Fatih Sultan Mehmet Training and Research Hospital|
|Istanbul, Atasehir, Turkey, 34758|
|Study Chair:||Niyazi Tug, Ass.Prof.||Executive and Educational Supervisor|